Litcius/Paper detail

Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors

Jordan Weinstein, Louis Girard, Serge Lepage, Robert S. McKelvie, Karthik Tennankore

2021Canadian Medical Association Journal32 citationsDOIOpen Access PDF

Abstract

KEY POINTS Hyperkalemia, defined as a serum potassium level of 5.0 mmol/L or greater, can lead to severe electrophysiological disturbances, including cardiac arrythmias, that increase morbidity and risk of death.[1][1] It is common in patients with conditions that impair potassium excretion by the

Topics & Concepts

HyperkalemiaAldosteroneRenin–angiotensin systemMedicinePotassiumInternal medicineEndocrinologyCardiologyPharmacologyChemistryBlood pressureOrganic chemistryPotassium and Related DisordersHeart Failure Treatment and ManagementPharmaceutical Practices and Patient Outcomes
Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors | Litcius